• Markets
  • icon
  • Companies
KZA · ASX

Kazia Therapeutics Ltd (ASX:KZA)

AU$0.08

 0.007 (9.589%)
ASX:Live
13/11/2023 12:00:00 AM
GROWTH AUS Big Candle All-Consensus All-Companies
Consensus Score
/10
Recommend
Target Price
Deviation
Unlock Full Consensus Insights

KZA Overview

KZA Health Scores

Short Term

Mean Revision

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Strong

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About KZA

Telephone

Address

Description

Kazia Therapeutics Ltd. is a clinical stage oncology company, which engages in the pharmaceutical research and development business. The company was founded by Graham Edmund Kelly in March 1994 and is headquartered in Sydney, Australia.

KZA Price Chart

Key Stats

Market Cap

AU$18.91M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.05 - 0.24

Trade Value (12mth)

AU$6,774.00

1 week

0%

1 month

-5.88%

YTD

-17.53%

1 year

-12.09%

All time high

33.1231

Key Fundamentals

EPS 3 yr Growth

-32.200%

EBITDA Margin

N/A

Operating Cashflow

-$15m

Free Cash Flow Return

-98.50%

ROIC

-133.40%

Interest Coverage

N/A

Quick Ratio

1.40

Other Data

Shares on Issue (Fully Dilluted)

228m

HALO Sector

Next Company Report Date

29-Aug-24

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

KZA Announcements

Latest Announcements

Date Announcements

31 October 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 October 23

Kazia announces short term unsecured Promissory Note

×

Kazia announces short term unsecured Promissory Note

31 October 23

Proposed issue of securities - KZA

×

Proposed issue of securities - KZA

31 October 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 October 19

Kazia presents to AusBiotech Invest

×

Kazia presents to AusBiotech Invest

31 October 16

Novogen Limited - In-licencing of Phase II-ready molecule - presentation (NRT-AU)

×

Novogen Limited - In-licencing of Phase II-ready molecule - presentation (NRT-AU)

31 May 22

GBM Agile opens to paxalisib in Europe

×

GBM Agile opens to paxalisib in Europe

31 July 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 23

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 January 22

Quarterly Activities/Appendix 4C Cash Flow Report

×

Quarterly Activities/Appendix 4C Cash Flow Report

31 August 23

Appendix 4E and 2023 Annual Report

×

Appendix 4E and 2023 Annual Report

31 August 23

Appendix 4G

×

Appendix 4G

31 August 23

2023 Corporate Governance Statement

×

2023 Corporate Governance Statement

31 August 11

Novogen Limited - Appendix 4E / Annual Report (NRT-AU)

×

Novogen Limited - Appendix 4E / Annual Report (NRT-AU)

30 September 19

Kazia presents Cantrixil poster at ESMO

×

Kazia presents Cantrixil poster at ESMO

30 September 10

Annual Report (NRT-AU)

×

Annual Report (NRT-AU)

30 September 09

Annual Report (NRT-AU)

×

Annual Report (NRT-AU)

30 October 18

Kazia presents to AusBiotech Invest

×

Kazia presents to AusBiotech Invest

30 October 12

Novogen Limited - Notification of SEC annual filing (NRT-AU)

×

Novogen Limited - Notification of SEC annual filing (NRT-AU)

30 October 06

2006 Annual Report

×

2006 Annual Report

30 May 22

Cleansing notice

×

Cleansing notice

30 June 22

Kazia progress update

×

Kazia progress update

30 August 17

Novogen Limited - Novogen annual report and full year financial results (NRT-AU)

×

Novogen Limited - Novogen annual report and full year financial results (NRT-AU)

30 August 17

Novogen Limited - Novogen annual report and Appendix 4E (NRT-AU)

×

Novogen Limited - Novogen annual report and Appendix 4E (NRT-AU)

29 September 23

Acceptance of late-breaking abstract of PNOC022 data

×

Acceptance of late-breaking abstract of PNOC022 data

29 November 21

GBM Agile opens to paxalisib in Canada

×

GBM Agile opens to paxalisib in Canada

29 March 12

Novogen Limited - Marshall Edwards CEO to present at Needham Conf (NRT-AU)

×

Novogen Limited - Marshall Edwards CEO to present at Needham Conf (NRT-AU)

KZA Fundamentals

Per Share Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Per Share, Growth & Valuations
EPS (Basic) $ Lock Lock Lock Lock -0.07 -0.19 -0.11 Lock Lock Lock
EPS (Fully Diluted) $ Lock Lock Lock Lock -0.07 -0.19 -0.11 Lock Lock Lock
     Growth % Lock Lock Lock Lock 56.2 -159.9 40.4 Lock Lock Lock
     PE X Lock Lock Lock Lock 186.0 N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock 45.4 N/A N/A Lock Lock Lock
CFPS $ Lock Lock Lock Lock -0.03 -0.17 -0.09 Lock Lock Lock
FCFPS $ Lock Lock Lock Lock -0.08 -0.17 -0.08 Lock Lock Lock
     Growth % Lock Lock Lock Lock 72.2 -447.1 48.5 Lock Lock Lock
     Yield % Lock Lock Lock Lock -5.9 -27.9 -51.3 Lock Lock Lock
DPS $ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock 0.0 N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS $ Lock Lock Lock Lock 0.29 0.13 0.05 Lock Lock Lock
BPS (Tangible) $ Lock Lock Lock Lock 0.12 -0.01 -0.02 Lock Lock Lock
     Growth % Lock Lock Lock Lock 590.8 -108.5 -125.0 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 118 132 184 Lock Lock Lock
Basic m Lock Lock Lock Lock 118 132 184 Lock Lock Lock

Financial Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Income Statement
Sales $m Lock Lock Lock Lock 15 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A -100.0 N/A Lock Lock Lock
Selling & General Expenses $m Lock Lock Lock Lock 20 23 22 Lock Lock Lock
Gross Income $m Lock Lock Lock Lock N/A -2 -2 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A 4.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
EBITDA $m Lock Lock Lock Lock -5 -23 -22 Lock Lock Lock
     Growth % Lock Lock Lock Lock 61.3 -389.3 2.8 Lock Lock Lock
     Margin % Lock Lock Lock Lock -30.9 N/A N/A Lock Lock Lock
Depreciation & Amortisation $m Lock Lock Lock Lock 1 2 2 Lock Lock Lock
EBIT $m Lock Lock Lock Lock -6 -25 -24 Lock Lock Lock
     Growth % Lock Lock Lock Lock 54.9 -318.1 2.9 Lock Lock Lock
     Margin % Lock Lock Lock Lock -39.2 N/A N/A Lock Lock Lock
Pretax Income $m Lock Lock Lock Lock -9 -25 -21 Lock Lock Lock
Income Taxes $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Income $m Lock Lock Lock Lock -8 -25 -20 Lock Lock Lock
     Growth % Lock Lock Lock Lock 32.4 -192.7 17.0 Lock Lock Lock
     Margin % Lock Lock Lock Lock -55.5 N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow $m Lock Lock Lock Lock -9 -23 -15 Lock Lock Lock
Capital Expenditures $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow $m Lock Lock Lock Lock 0 -2 0 Lock Lock Lock
Net Financing Cash Flow $m Lock Lock Lock Lock 28 4 13 Lock Lock Lock
Free Cash Flow $m Lock Lock Lock Lock -9 -23 -15 Lock Lock Lock
     Growth % Lock Lock Lock Lock -3.4 -149.9 33.6 Lock Lock Lock
     Margin % Lock Lock Lock Lock -0.6 N/A N/A Lock Lock Lock
Franking Balance $m Lock Lock Lock Lock N/A N/A 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments $m Lock Lock Lock Lock 28 7 5 Lock Lock Lock
Total Assets $m Lock Lock Lock Lock 58 35 28 Lock Lock Lock
Long Term Debt $m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt $m Lock Lock Lock Lock -28 -7 -3 Lock Lock Lock
Total Liabilities $m Lock Lock Lock Lock 20 16 16 Lock Lock Lock
Equity $m Lock Lock Lock Lock 38 19 12 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 38 19 12 Lock Lock Lock
     Growth % Lock Lock Lock Lock 168.0 -50.8 -35.3 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -14.5 -70.5 -72.9 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -22.3 -132.2 -169.8 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -22.9 -88.1 -148.7 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -32.4 -87.3 -133.4 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -35.1 -80.6 -98.5 Lock Lock Lock

Ratios Records

Historical data

Forecasted data

AUD 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 5.9 0.3 0.2 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -72.9 -39.5 -28.6 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 3.5 1.6 1.4 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 3.5 1.6 1.4 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 93.9 96.8 48.7 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -109.4 -485.8 -199.8 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 23.7 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.7 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 12.5 N/A 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.3 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.3 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock -58.7 N/A 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock -15.3 N/A 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -14.5 -70.5 -72.9 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.5 1.9 2.3 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -22.3 -132.2 -169.8 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -22.3 -132.2 -169.8 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock N/A N/A 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 15.4 N/A 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 15.4 N/A 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock N/A 319.3 232.5 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock 15.4 -319.3 -232.5 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

0.00%

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

KZA Shortsell

Frequently Asked Questions

The current share price of Kazia Therapeutics Ltd (KZA:ASX) is AU$0.08.
The 52-week high share price for Kazia Therapeutics Ltd (KZA:ASX) is AU$0.24.
The 52-week low share price for Kazia Therapeutics Ltd (KZA:ASX)? is AU$0.05.
Kazia Therapeutics Ltd (KZA:ASX) does not pay a dividend.
Kazia Therapeutics Ltd (KZA:ASX) does not pay a dividend.
Kazia Therapeutics Ltd (KZA:ASX) has a franking level of 0%.
Kazia Therapeutics Ltd (KZA:ASX) is classified in the Healthcare.
The current P/E ratio for Kazia Therapeutics Ltd (KZA:ASX) is .